Compare Gartner Inc (IT) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gartner Inc vs Repligen Corporation Common Stock — how do they compare? Gartner Inc trades at $197.48 (market cap $12.44B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Gartner Inc and Repligen Corporation Common Stock are close in size by market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Gartner Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Gartner Inc for 65 Days and Repligen Corporation Common Stock for 0 Days on average.
| IT | RGEN | |
|---|---|---|
Market Cap | $12.44B | $11.14B |
Volume | 818,587 | 1,259,263 |
Sector | Technology | Health |
52-Week High | $258.17 | $194.57 |
52-Week Low | $125.68 | $102.87 |
Typical Hold Time | 65 Days | 0 Days |
Enterprise Value | $14.18B | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gartner Inc. (IT) trades at $195.77, up 0.86% on the day, with a bullish technical signal and strong profitability metrics including a 69.63% gross margin and 113.58% ROE. Recent earnings beats and positive news flow around AI advisory demand support the stock, though net cash flow turned negative in 2025. The current price sits above the consensus target of $178.14, indicating potential overvaluation concerns among analysts.
Outlook remains positive due to robust contract value growth and AI-driven demand, but risks include volatile cash flows, high P/B ratio of 160.06, and a shareholder investigation. Investor sentiment is mixed with 55.55% hold ratings, suggesting cautious optimism amid execution risks and macroeconomic uncertainty.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gartner Inc
Based in Stamford, Conn., Gartner provides independent research and analysis on information technology and other related technology industries. Its research is delivered to clients' desktops in the form of reports, briefings, and updates. Typical clients are chief information officers and other business executives who help plan companies' IT budgets. Gartner also provides consulting services and hosted nearly 80 IT conferences across the globe in 2007.
Read more on IT →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
